ProMIS Neurosciences Inc (PMN)

Currency in USD
14.860
+0.070(+0.47%)
Closed·
14.600-0.260(-1.75%)
·
Advertisement
PMN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14.45015.280
52 wk Range
6.27027.400
Key Statistics
Prev. Close
14.79
Open
15.28
Day's Range
14.45-15.28
52 wk Range
6.27-27.4
Volume
29.86K
Average Volume (3m)
81.99K
1-Year Change
-3.6629%
Book Value / Share
6.77
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PMN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
44.035
Upside
+196.33%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

ProMIS Neurosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 44.035
(+196.33% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Guggenheim
Buy100.00+572.95%69.00Maintain14/08/2026
Guggenheim
Buy69.00+364.33%35.00Maintain29/07/2026
Chardan
Buy33.00+122.07%20.00Maintain28/07/2026
Chardan
Buy20.00+34.59%-New Coverage27/07/2026
H.C. Wainwright
Buy18.00+21.13%-Maintain15/07/2026

ProMIS Neurosciences Inc Earnings Call Summary for Q2/2026

  • ProMIS ended Q2 with CAD 53.4M cash vs CAD 6.1M at year-end 2025, sufficient to fund operations through 2027 and Q1 2027 data readout.
  • Q2 net loss widened to CAD 11.7M (CAD 1.28/share) from CAD 10.1M (CAD 7.26/share) year-over-year, driven by increased clinical activity.
  • Alzheimer's drug PMN310 showed positive interim safety data with zero ARIA-E cases; PRECISE-AD trial enrolled 144 patients across 21 U.S. sites.
  • Management preparing for potential single registration study if Q1 2027 data remain positive; holds FDA Fast Track designation for PMN310.
  • Pipeline expansion includes PMN267 for ALS and PMN442 for synucleinopathies, both expected to enter clinic within 6-9 months.
Last Updated: 13/08/2026, 22:50
Read Full Transcript

Earnings

Latest Release
12/05/2026
EPS / Forecast
-1.26 / -0.18
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare PMN to Peers and Sector

Metrics to compare
PMN
Peers
Sector
Relationship
P/E Ratio
−3.2x−2.3x−0.4x
PEG Ratio
0.00−0.040.00
Price/Book
2.7x1.4x2.6x
Price / LTM Sales
-2.2x3.1x
Upside (Analyst Target)
139.2%640.9%47.8%
Fair Value Upside
Unlock0.7%6.2%Unlock

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
5.68K0.06%84.35K
Other Institutional Investors
10.00M99.94%148.53M
Public Companies & Retail Investors
0.000.00%0.00
Total
10M100.00%148.61M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Janus Henderson Group Ltd.14.42%1,292,75719,210
Deep Track Capital, LP9.32%835,65512,418

People Also Watch

2.785
XTLB
-0.54%
14.830
DSGN
+3.06%
1.150
EZGO
-6.50%
58.08
KFRC
-3.92%
17.920
NDLS
+6.41%

FAQ

What Is the ProMIS Neurosciences (NASDAQ: PMN) Share Price Today?

The ProMIS Neurosciences stock price today is 14.860 USD.

What Stock Exchange Does ProMIS Neurosciences (PMN) Trade On?

ProMIS Neurosciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for ProMIS Neurosciences?

The stock symbol (also called a 'ticker') for ProMIS Neurosciences is "PMN."

What Is the Current ProMIS Neurosciences Market Capitalisation?

As of today, ProMIS Neurosciences (NASDAQ: PMN) market cap is 132.630M USD.

What Is ProMIS Neurosciences's (PMN) Earnings Per Share (TTM)?

The ProMIS Neurosciences EPS is currently -13.360 (Trailing Twelve Months).

When Is the Next ProMIS Neurosciences Earnings Date?

ProMIS Neurosciences's next earnings report will be released on 12/05/2026.

Is PMN a Buy or Sell From a Technical Analyst Perspective?

Based on today's ProMIS Neurosciences moving averages and other technical indicators, the daily buy/sell signal for PMN stock is Strong Buy.

How Many Times Has ProMIS Neurosciences Stock Split?

ProMIS Neurosciences has split 2 times. (See the PMN stock split history page for full effective split date and price information.)

How Many Employees Does ProMIS Neurosciences Have?

ProMIS Neurosciences has 11 employees, based on their latest Companies House report.

What is the current trading status of ProMIS Neurosciences (NASDAQ: PMN)?

As of 15/08/2026, ProMIS Neurosciences (PMN) is trading at a share price of 14.860 USD, with a previous close of 14.790 USD. The stock has fluctuated within a day range of 14.450 USD to 15.280 USD, while its 52-week range spans from 6.270 USD to 27.400 USD.

What Is ProMIS Neurosciences (PMN) Price Target According to Analysts?

The average 12-month price target for ProMIS Neurosciences is 44.035 USD, with a high estimate of 100.48075537 USD and a low estimate of 18.23554851 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +196.33% Upside potential.

What Is the PMN Premarket Price?

PMN's last pre-market stock price is 15.050 USD. The pre-market share volume is 790.000, and the stock has decreased by 0.260, or 1.760%.

What Is the PMN After Hours Price?

PMN's last after hours stock price is 14.600 USD, the stock has decreased by -0.260, or -1.750%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.